NOVO-ACEBUTOLOL (TYPE S) TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE)

Доступна с:

NOVOPHARM LIMITED

код АТС:

C07AB04

ИНН (Международная Имя):

ACEBUTOLOL

дозировка:

400MG

Фармацевтическая форма:

TABLET

состав:

ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 400MG

Администрация маршрут:

ORAL

Штук в упаковке:

100

Тип рецепта:

Prescription

Терапевтические области:

BETA-ADRENERGIC BLOCKING AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0131282002; AHFS:

Статус Авторизация:

CANCELLED PRE MARKET

Дата Авторизация:

2015-10-16

Характеристики продукта

PRODUCT MONOGRAPH
Pr
NOVO-ACEBUTOLOL (TYPE S)
(Acebutolol Hydrochloride)
100, 200 and 400 mg Tablets
Novopharm Standard
ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT
Novopharm Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No: 103290, 110614
Date of Preparation:
May 11, 2007
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT
INFORMATION.........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS....................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE
REACTIONS....................................................................................................8
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE.................................................................................................................11
ACTION AND CLINICAL
PHARMACOLOGY.............................................................12
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND
PACKAGING..............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL
INFORMATION..........................................................................15
CLINICAL TRIALS
..........................................................................................................16
DETAILED PHARMACOLOGY
.......................................................